Apheresis and Immune Complex Removal: What the Research Shows

One of the most persistent and underappreciated drivers of chronic Lyme disease symptoms is not the bacteria itself — it is what the immune system's prolonged response to bacteria leaves behind. Circulating immune complexes, autoantibodies, pro-inflammatory cytokines, and bacterial debris accumulate in the bloodstream over months and years of active infection, and they do not simply clear when the pathogen load is reduced. They continue to signal inflammation, deposit in tissues, and drive immune dysfunction long after antimicrobial treatment has done its work.

Therapeutic apheresis — extracorporeal blood filtration — addresses this accumulated burden directly. And the scientific basis for this approach extends well beyond Lyme disease, grounded in decades of research on immune complex-mediated disease across multiple chronic inflammatory conditions. This article reviews research retrieved from PubMed that establishes the clinical rationale for apheresis as a component of advanced Lyme disease treatment.

Understanding immune complexes and why they matter in Lyme disease

An immune complex forms when an antibody binds to its target antigen — in the case of Lyme disease, Borrelia surface proteins and bacterial debris — and the resulting structure circulates in the bloodstream. In normal, acute infection, immune complexes are cleared efficiently by the liver and spleen. In chronic Lyme, where immune dysregulation has impaired these clearance mechanisms, immune complexes accumulate beyond the body's capacity to remove them.

Once circulating immune complexes reach sufficient concentrations, they begin to deposit in blood vessel walls, joint tissues, and organ membranes. This deposition triggers local complement activation and inflammatory cascades that are largely independent of whether the original pathogen is still present. The inflammatory damage continues because the immune complex burden continues — not because the infection is still actively spreading.

This mechanism explains one of the most frustrating clinical realities of chronic Lyme: patients whose Borrelia has been addressed with antibiotics who continue to experience worsening inflammation. The bacteria have been partially or substantially eliminated, but the immune complex burden and its downstream consequences persist.

Study 1: The scientific rationale for extracorporeal immune complex removal

This review published in Blood Purification provides a foundational overview of the rationale and technical evolution of extracorporeal immune complex removal — the same biological principle underlying therapeutic apheresis in chronic inflammatory conditions.

The authors review the history of immune complex-mediated disease, beginning with serum sickness — where antibodies against circulating foreign proteins form immune complexes that trigger systemic complement activation, vasculitis, and multi-organ inflammation. This historical model established the core principle: circulating immune complexes are directly causal to inflammatory disease, and removing them reduces that disease.

The review traces the evolution of immune complex removal technology from non-selective plasma exchange — which removes all plasma components — toward increasingly specific techniques that can selectively target particular immune complex types. The authors document that circulating immune complexes have been detected across a wide range of chronic systemic diseases, including autoimmune disorders, infections, and cancer — establishing immune complex accumulation as a broadly relevant mechanism in chronic illness, not a phenomenon limited to any single disease category.

Study 2: Immunoadsorption achieves 88% response in steroid-refractory inflammatory disease

This retrospective clinical study examined the efficacy of immunoadsorption — a selective form of extracorporeal blood filtration that specifically removes autoantibodies and immune complexes — in 60 patients with multiple sclerosis relapses that had failed to respond to high-dose steroid treatment.

The results were clinically significant. Of 60 patients treated with immunoadsorption, 53 (88%) showed clinically relevant improvement in their primary MS symptoms. The response emerged gradually, with symptomatic improvement first registered on average after the third session. Only 4 serious complications occurred across 396 individual treatment sessions — a complication rate of 1% — with mild side effects in 4% of sessions.

The study found that 87.5% of patients could be treated through peripheral venous access rather than a central venous catheter, allowing the procedure to be performed on an outpatient basis — the same approach used in our clinical setting.

While multiple sclerosis and chronic Lyme disease are distinct conditions, they share mechanistic features that make this research directly relevant. Both involve autoantibodies, circulating immune complexes, and a dysregulated inflammatory response that contributes to neurological and systemic symptoms. The immunoadsorption technology that removed autoantibodies and immune complexes in MS patients operates on the same biological principles as the apheresis used in advanced Lyme care.

Why these findings are relevant to chronic Lyme disease specifically

Research retrieved from PubMed on immune complex-mediated inflammation and extracorporeal removal supports several conclusions with direct relevance to chronic Lyme disease:

• Immune complex accumulation is a driver of chronic inflammation independent of active pathogen burden. This explains why Lyme symptoms can persist and worsen even after antibiotic treatment — the inflammatory burden has decoupled from the infection.
• Extracorporeal removal of immune complexes and autoantibodies is clinically effective in inflammatory conditions driven by these mechanisms. The 88% response rate in MS immunoadsorption demonstrates that targeting the molecular load — rather than the disease cause — produces measurable clinical benefit.
• The technology has an established safety profile. Decades of clinical experience across multiple conditions have characterized the risks and management of apheresis procedures, with serious complication rates in the 1% range in well-supervised settings.

The parallels between chronic Lyme and other immune complex-driven conditions

Chronic Lyme disease shares immune complex-driven mechanisms with several conditions for which apheresis has established clinical precedent:

How apheresis fits within a coordinated treatment approach

The research makes clear that apheresis is most meaningful not as a standalone cure, but as a component of a coordinated therapeutic sequence. Removing immune complexes and inflammatory mediators from the bloodstream does not address the immune dysregulation that generated them — it creates the physiological conditions in which subsequent immune interventions can operate more effectively.

At the Lyme Immunotherapy Center, apheresis is positioned as a preparatory and supportive intervention within our programs — reducing the inflammatory burden before Treg therapy so that reinfused regulatory cells encounter a less hostile environment, and clearing the debris mobilized by systemic hyperthermia so the body is not left managing an increased inflammatory load without support.

The science on immune complex-mediated inflammation, and on the clinical effectiveness of extracorporeal removal techniques, provides the mechanistic foundation for this approach. It is not a claim that apheresis cures Lyme disease. It is a recognition that accumulated inflammatory burden is a real, measurable, and addressable component of chronic Lyme pathology — and that addressing it directly opens therapeutic opportunities that conventional treatment cannot access.